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Abstract: Transient receptor potential classical or canonical 4 (TRPC4) and TRPC5 channels
are members of the classical or canonical transient receptor potential (TRPC) channel family of
non-selective cation channels. TRPC4 and TRPC5 channels are widely accepted as receptor-operated
cation channels that are activated in a phospholipase C-dependent manner, following the Gq/11
protein-coupled receptor activation. However, their precise activation mechanism has remained
largely elusive for a long time, as the TRPC4 and TRPC5 channels were considered as being insensitive
to the second messenger diacylglycerol (DAG) in contrast to the other TRPC channels. Recent findings
indicate that the C-terminal interactions with the scaffolding proteins Na+/H+ exchanger regulatory
factor 1 and 2 (NHERF1 and NHERF2) dynamically regulate the DAG sensitivity of the TRPC4 and
TRPC5 channels. Interestingly, the C-terminal NHERF binding suppresses, while the dissociation of
NHERF enables, the DAG sensitivity of the TRPC4 and TRPC5 channels. This leads to the assumption
that all of the TRPC channels are DAG sensitive. The identification of the regulatory function of the
NHERF proteins in the TRPC4/5-NHERF protein complex offers a new starting point to get deeper
insights into the molecular basis of TRPC channel activation. Future studies will have to unravel the
physiological and pathophysiological functions of this multi-protein channel complex.
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1. Introduction
Transient receptor potential classical or canonical 4 (TRPC4) and TRPC5 channels belong to the
transient receptor potential classical or canonical (TRPC) cation channel subfamily, which comprises
seven members. TRPC channels are regarded as non-selective, receptor-operated cation channels
that are important for calcium homeostasis. They are activated via the Gq/11-signaling cascade as
a function of phospholipase C (PLC) [1]. Moreover, the TRPC4 and TRPC5 channels can also be
activated following the Gi/o-protein coupled receptor activation [2–4]. However, the mechanism of
the Gi/o-mediated TRPC4/5 channel activation is still not completely understood and might involve
either a direct Gi/o-protein interaction [3], or the activation of the PLC isoform, PLCδ1 [2]. Even
a Gs-protein mediated activation mechanism was proposed for the TRPC5 channels [5]. Therefore,
elevating the intracellular cyclic adenosine monophosphate (cAMP) levels might potentiate the TRPC5
currents by increasing the channel trafficking to the plasma membrane. Additionally, a store-operated
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activation mechanism for the TRPC4 [6–9] and TRPC5 channels [10–12] was proposed, and is still
under discussion [13,14]. This article will only focus on the Gq/11-protein mediated signaling pathway
leading to the TRPC4 and TRPC5 channel activation.
All of the TRPC channels are tetramers formed by four TRPC protein subunits, which was
confirmed recently by structural analysis [15–18]. TRPC proteins can form not only homotetrameric
but also heterotetrameric cation channels [19–22] with distinct channel properties, such as altered
calcium permeability [21,23–25]. Because of their sequence homology, the TRPC channel family
can be divided into the following subgroups: TRPC1, TRPC4/5, and TRPC3/6/7. TRPC2 has a
special role as it represents a pseudogene in humans that is not functionally expressed because of
several stop codons in the open reading frame [26,27]. However, in rodents, the TRPC2 channels are
functionally expressed (e.g., in the olfactory cells of the vomeronasal organ, where they are important
for pheromone sensing [28]).
Although the Gq/11-protein mediated TRPC channel activation is widely accepted, the precise
signaling pathway resulting in the channel opening has remained elusive for quite some time.
The activation of the Gq/11-protein coupled receptors leads to the activation of PLC, which cleaves
phosphatidylinositol-4,5-bisphosphate (PIP2) into the second messengers, inositol-1,4,5-trisphopshate
(IP3) and 1,2-diacyl-sn-glycerol (DAG), and to an oxonium ion [29,30]. There is broad agreement that
the TRPC3/6/7 subfamily is directly activated by DAG, the cleavage product of PIP2 [31]. However,
IP3 might also contribute to the activation of endogenously expressed TRPC7 channels [32]. Notably,
a DAG binding site has not been identified until now, and it is not clear whether DAG directly activates
the channel or whether it first interacts with an additional protein, which in turn causes the channel
activation. Unfortunately, the recent structural analysis of the TRPC3, TRPC4, and TRPC6 channels
only displays a closed channel conformation [15–18]. However, the structural model of TRPC3 reveals
two lipid-binding sites, one being sandwiched between the pre-S1 elbow and the S4–S5 linker, and the
other being close to the pore-forming domain, where the conserved “LWF” motif of the TRPC family
is located [16]. Perhaps these lipid binding sites reflect potential DAG binding sites. Interestingly,
it was recently reported that the exchange of a highly conserved amino acid located close to the
pore-forming domain, affects the DAG recognition of the TRPC3 channels [33]. Thus, the second lipid
binding site might indeed reflect a potential DAG binding site. TRPC2 channels are also regarded
as being DAG sensitive [34,35]. In contrast to the TRPC2, TRPC3, TRPC6, and TRPC7 channels,
the TRPC4 and TRPC5 channels were commonly considered as DAG insensitive [31], as DAG or the
membrane permeable DAG analogue 1-oleoyl-2-acetyl-sn-glycerol (OAG) even inhibited the basal
TRPC5 currents [36]. Interestingly, Venkatachalam and colleagues showed that the DAG-induced
TRPC5 channel inhibition is related to the protein kinase C (PKC) activation [36]. Moreover,
it was demonstrated that the homotetrameric TRPC4 and TRPC5 channels are activated by PIP2
depletion [37,38]. In contrast, the heterotetrameric TRPC1/4 and TRPC1/5 [39] and homotetrameric
TRPC6 and TRPC7 channels [40] are instead inhibited by the PIP2 depletion. These contradictory
findings suggest that the TRPC channel-lipid interaction is rather complex. Another unique structural
feature of the TRPC4 and TRPC5 channels is their capability to interact with the PDZ I domain of the
scaffolding proteins Na+/H+ exchanger regulatory factor 1 and 2 (NHERF1 and NHERF2) [41–43].
The NHERF1 and NHERF2 proteins are structurally related; can form homodimers [44]; and possess
two PDZ binding domains as well as a C-terminal binding domain, which enables crosslinking with
the actin cytoskeleton via ezrin, radixin, and moesin proteins [41,45]. Thus, NHERF1 and NHERF2
proteins are commonly regarded as adapter proteins that crosslink integral membrane proteins with
the cytoskeleton, thereby increasing their membrane localization [46–48].
2. DAG-Mediated Activation Mechanism of TRPC4 and TRPC5 Channels
The first evidence that the TRPC5 channels might be DAG sensitive was presented by Lee and
colleagues, who performed electrophysiological whole-cell measurements on murine gastric smooth
muscle cells endogenously expressing TRPC5 channels, and found that the channels are activated by
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OAG [49]. However, the mechanistic insights into the DAG mediated TRPC5 channel activation were
missing. A remarkable structural difference between TRPC4 and TRPC5, and the well characterized
DAG sensitive TRPC3/6/7 channels, is the PDZ binding motif with the amino acid sequence “VTTRL”
at the very end of the C-terminus [41,42,50]. This PDZ binding motif includes a potential PKC
phosphorylation site, which was identified as being important for the TRPC5 current inactivation
following the receptor activation [51]. The amino acid exchange from threonine to alanine at position
972 (T972A) in the murine TRPC5 channels resulted in a loss of current desensitization during the
receptor activation with carbachol [51]. Thus, this was the first evidence that the PKC phosphorylation
might regulate the TRPC5 channel function [36,51].
The C-terminal PDZ binding motif allows for interactions with the adapter proteins NHERF1
and NHERF2. This C-terminal TRPC4/5 interaction was demonstrated several times by performing
co-immunoprecipitations and functional studies using the patch-clamp technique [41–43]. However,
only a slight enhancement of the membrane expression was found to be similar to what was
observed when analyzing the chloride channel cystic fibrosis transmembrane conductance regulator
(CFTR) [52] and other integral membrane proteins. Thus, the functional implications of the
TRPC4/5-NHERF interaction were missing. Interestingly, our recent findings indicate that the TRPC4
and TRPC5 channels are DAG-sensitive similar to other TRPC channels [53]. However, in contrast
to TRPC3/6/7, their DAG-sensitivity is tightly regulated by the C-terminal NHERF1 and NHERF2
interaction. The Gq/11-protein coupled receptor activation causes a cleavage of PIP2, resulting in
a conformational change of the C-terminus, which in turn causes the dissociation of the NHERF
proteins from the C-terminus of the channel. This dynamic dissociation was monitored employing the
method of dynamic intermolecular fluorescence resonance energy transfer (FRET) between fluorescence
tagged TRPC5 and NHERF proteins. The separation of the NHERF proteins from the C-terminus
was a prerequisite for DAG sensitivity. Moreover, the C-terminal NHERF interaction strongly
depended on the PKC phosphorylation status of the C-terminal PDZ binding motif “VTTRL” [53].
The PKC inhibition resulted in the DAG sensitivity, and the PKC phosphorylation mutant T972A
of murine TRPC5 was sensitive to DAG, suggesting that PKC phosphorylation is a prerequisite for
NHERF binding, thereby suppressing the DAG sensitivity. Thus, the NHERF proteins are dynamic
regulators of the TRPC4 and TRPC5 channel activity. This signaling pathway was also observed in the
primary cell lines (e.g., in proximal tubule cells and in hippocampal neurons, which endogenously
express TRPC4 and TRPC5 channels, respectively) [53]. This activation model has the potential to
integrate the contradictory findings of different research groups concerning the TRPC4 and TRPC5
channel activation. Therefore, the pieces of the puzzle like the PLC dependent receptor-mediated
TRPC4/5 channel activation [1], the inhibitory effect of DAG or DAG analogues [31,36] on the native
TRPC4/5-NHERF-channel complex [41–43], the activation by PIP2 depletion [37,38], the inhibitory
effect of PKC phosphorylation on DAG sensitivity [36], and the DAG sensitivity of the endogenous
gastric TRPC5 channels [49] coalesce into a consistent picture. These findings lead to a new
concept, that all of the TRPC channels are DAG-sensitive, and that classifying the TRPC channels as
DAG-sensitive and -insensitive channels should be avoided. Consequently, a common DAG binding
site for TRPC channels can be proposed. Perhaps the highly conserved amino acid near the TRPC pore
domain that affects the DAG activation [33] participates in DAG binding.
Altogether, a new model of Gq/11-protein mediated TRPC4 and TRPC5 channel activation can be
proposed. The agonist-induced Gq/11-protein coupled receptor activation causes the activation of PLC,
which in turn cleaves PIP2 into the two second messengers IP3 and DAG. The PIP2 cleavage causes
a conformational change at the C-terminus of TRPC4 and TRPC5, which results in a dissociation of
the NHERF proteins from the C-terminus, thereby evoking a DAG-sensitive channel conformation.
Then, the PIP2 cleavage product DAG can activate the channel. This model is illustrated in Figure 1.
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Figure 1. Diacylglycerol (DAG)-mediated activation of transient receptor potential classical or 
canonical 4/5 (TRPC4/5) channels. Left: Na+/H+ exchanger regulatory factor (NHERF) proteins and 
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the closed state of the channel. Right: receptor activation (not displayed) leads to the cleavage of PIP2, 
resulting in the dissociation of NHERF and in DAG binding, which represents the open state of the 
channel. Sodium cations (dark green circles), calcium cations (light green circles), and potassium 
cations (yellow circles) are displayed. The potassium efflux is mainly relevant in the excitable cells. 
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NHERF1 and NHERF2 proteins belong to a family of scaffolding proteins that crosslink the 
integral membrane proteins with the cytoskeleton. It is commonly accepted that NHERF proteins 
increase the membrane localization of several membrane proteins, like transporters, receptors, and 
ion channels [46–48]. However, besides their anchoring function, the NHERF proteins are of the 
utmost importance for the maintenance of essential cellular functions (e.g., in the kidney or in the 
small intestine, where they interact with transporters, ion channels, signaling proteins, transcription 
factors, enzymes, G-protein coupled receptors, and tyrosine kinase receptors) [47,48,54–56]. Thus, 
NHERF proteins are involved in numerous physiological processes. For example, in proximal tubule 
cells, NHERF proteins regulate phosphate transport [57]. A mutation in the PDZ I domain of human 
NHERF1 was found in patients with impaired renal phosphate reabsorption due to a reduced 
expression of the renal phosphate transporter NPT2a [58]. In astrocytes, NHERF proteins regulate 
the activity of the glutamate transporter (GLAST) and of the metabotropic glutamate receptor 
(mGlu5) [59,60], and in the small intestine, they control ion transport via interactions with the Na+/H+ 
exchanger (NHE3) [61]. Moreover, the mice lacking NHERF1 and adult humans harboring NHERF1 
mutations suffer from osteopenia [62,63], which might be due to abnormal osteoblast differentiation 
[64]. Furthermore, NHERF proteins influence proliferation [65,66], and they may be involved in 
carcinogenesis and in the progression of liver, breast, and colon cancer; small-cell lung carcinoma; 
and glioblastoma [67–70]. A mutation in the PDZ I domain of NHERF1 was identified in the patients 
with medullar breast carcinoma [71]. This mutation resulted in a reduced interaction of NHERF1 with 
Figure 1. Diacylglycerol (DAG)-mediated activation of transient receptor potential classical or
canonical 4/5 (TRPC4/5) channels. Left: Na+/H+ exchanger regulatory factor (NHERF) proteins and
phosphatidylinositol-4,5-bisphosphate (PIP2) interact with the C-termini of TRPC4/5, which depicts
the closed state of the channel. Right: receptor activation (not displayed) leads to the cleavage of
PIP2, resulting in the dissociation of NHERF and in DAG binding, which represents the open state of
the channel. Sodium cations (dark green circles), calcium cations (light green circles), and potassium
cations (yellow circles) are displayed. The potassium efflux is mainly relevant in the excitable cells.
3. Physiological and Pathophysiological Roles f NHERF Proteins
NHERF1 and NHERF2 proteins belong to a family of scaffolding proteins that crosslink the
integral membrane proteins with the cytoskeleton. It is commonly accepted that NHERF proteins
increase the membrane localization of several membrane proteins, like transporters, receptors, and ion
channels [46–48]. However, besides their anchoring function, the NHERF proteins are of the utmost
importance for the maintenance of essential cellular functions (e.g., in the kidney or in the small
intestine, where they interact with transporters, ion channels, signaling proteins, transcription factors,
enzymes, G-protein coupled receptors, and tyrosine kinase receptors) [47,48,54–56]. Thus, NHERF
proteins are involved in numerous physiological processes. For example, in proximal tubule cells,
NHERF proteins regulate phosphate transport [57]. A mutation in the PDZ I domain of human NHERF1
was found in patients with impaired renal phosphate reabsorption due to a reduced expression of the
renal phosphate transporter NPT2a [58]. In astrocytes, NHERF proteins regulate the activity of the
glutamate transporter (GLAST) and of the metabotropic glutamate receptor (mGlu5) [59,60], and in
the small intestine, they control ion transport via interactions with the Na+/H+ exchanger (NHE3) [61].
Moreover, the mice lacking NHERF1 and adult humans harboring NHERF1 mutations suffer from
osteopenia [62,63], which might be due to abnormal osteoblast differentiation [64]. Furthermore,
NHERF proteins influence proliferation [65,66], and they may be involved in carcinogenesis and in
the progression of liver, breast, and colon cancer; small-cell lung carcinoma; and glioblastoma [67–70].
A mutation in the PDZ I domain of NHERF1 was identified in the patients with medullar breast
carcinoma [71]. This mutation resulted in a reduced interaction of NHERF1 with the epidermal
growth factor receptor, thereby promoting the progression of breast cancer. Another mutation in the
PDZ II domain of human NHERF1 resulted in a nuclear translocation of NHERF1, thereby inducing
carcinogenesis [72]. Recently, in the tumors from ovarian cancer patients, a mutation in the PDZ II
domain of NHERF1 was identified, which might contribute to the disease progression [73]. These data
suggest that wild-type NHERF1 may act as a tumor suppressor. The subcellular ERF expression
also plays a critical role in cancer cells. In breast cancer cells, the subcellular NHERF expression might
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even serve as a prognostic marker, as a high cytoplasmic expression of NHERF was associated with
a high aggressiveness and poor prognosis [74]. Furthermore, aberrant nuclear NHERF1 expression
might be important for the carcinogenesis and progression of colon [74] and breast cancer [72].
The specific role of NHERF proteins for channel function is poorly understood. Beside the
regulatory role of NHERF proteins on TRPC4 and TRPC5 channel function [53], the interaction with
NHERF was identified as playing an important role in the proper function of the CFTR chloride
channel [52]. Mutations in the CFTR channel are known to cause cystic fibrosis [75], which is
characterized by the accumulation of viscous mucus, because of impaired fluid transport. Furthermore,
CFTR mutations can cause congenital absence of the vas deferens and male infertility [76]. Interestingly,
the NHERF2 interaction with the lysophosphatidic acid receptor 2 (LPAR2) promotes the assembly
of CFTR–NHERF2–LPAR2 protein complexes, which results in an impaired CFTR function [77,78].
The disruption of this protein complex might enhance the CFTR function of patients suffering from
cystic fibrosis [52]. Altogether, the NHERF proteins or their protein complexes might be interesting
novel targets for the treatment of diseases
4. Physiological and Pathophysiological Roles of TRPC4 and TRPC5 Channels
TRPC4 and TRPC5 channels are expressed in several cells and tissues (e.g., in the brain [79–83],
kidney [80,84,85], and vascular system [7,8,86]). In particular, the TRPC4 and TRPC5 channel
expression is very high in the central nervous system [7,79,82]. Here, the TRPC4 and TRPC5
channels are involved in the amygdala function and account for fear-related behavior against aversive
stimuli [87,88]. In addition, the TRPC4 and TRPC5 channels are important for peripherally induced
neuropathic pain behavior. Microinjections of the TRPC4 and TRPC5 channel blocker ML-204 into
the amygdala of rats reduced the sensory and the affective pain sensitivity [89]. Thus, in the future,
TRPC4/5 blockers that are able to cross the blood–brain barrier might be used as novel anxiolytics or
even as innovative analgesics against peripheral neuropathies. Furthermore, the TRPC4 and TRPC5
channels are expressed in the dorsal root ganglia, where they contribute to axonal regeneration after
nerve injury [90], to itching [91], and to cold detection [92].
Moreover, in the hippocampal CA1 pyramidal cells from rats, the calcium and sodium influx
through the TRPC5 channels generated a plateau potential [93] that is also observed during epileptic
seizures [94,95]. In accordance with this neurophysiological evidence, the TRPC5 gene-deficient mice
exhibited significantly reduced seizures. Thus, future studies will have to show whether TRPC5
channels represent interesting novel target structures for the treatment of epileptic disorders.
Furthermore, the TRPC5 channels reduce the hippocampal neurite length and growth cone
morphology by reducing the filopodia length growth, which leads to impaired axon guidance [96].
The TRPC5 channels also play a role in podocytes and in fibroblasts. Interestingly, in these
cells, the TRPC5 and TRPC6 channels have opposite effects on the actin cytoskeleton [97]. The
receptor-operated TRPC5 channel activation by angiotensin II decreased the number of parallel stress
fibers via the activation of the small guanosine-5′-triphosphate (GTP)ase protein Rac1, leading to a
motile and non-contractile phenotype in vitro, while the TRPC6 activation by angiotensin II increased
the formation of parallel stress fibers via the activation of the small GTPase protein Rho A, resulting in
a contractile but non-motile phenotype [97]. These differential channel functions might be due to a
specific subcellular localization of TRPC5 and TRPC6 channels in podocytes, or be caused by a distinct
signaling elicited by the podocyte-specific TRPC6 and slit membrane protein channel complex [98,99].
The reorganization of the actin cytoskeleton characterized by a reduction of the parallel stress fibers
results in podocyte injury, leading to the loss of podocyte foot processes, which in the end results
in the disruption of the slit diaphragm and in massive proteinuria [100–102]. Thus, the TRPC5
channel blockers might be useful for the treatment of podocyte diseases by preventing end-stage renal
disease [103,104].
In addition, the TRPC4 and TRPC5 channels might play a pathophysiological role in cancer
cells. The increased TRPC5 channel activity in breast cancer [105] and in colorectal cancer
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cells [106] caused an increased expression of the ABC transporter P-glycoprotein (MDR1). MDR1
is an important molecular correlate for drug-resistance against chemotherapeutic agents. For example,
MDR1 eliminates the well-known and commonly used DNA intercalating drug doxorubicin, the
tubulin-targeting drug paclitaxel, and the antimetabolite 5-fluorouracil. In breast cancer cells, the
transcription factor NFATc3, and in colorectal cancer cells, the structural protein and transcription
factor β-catenin, are thought to enhance the MDR1 expression [105,106]. In contrast, the potent TRPC4
and TRPC5 channel activator (-)-englerin A showed pronounced cytotoxic effects on diverse cancer
cell lines, with an EC50 value of ~ 20 nM [107,108]. (-)-englerin A was even effective on triple-negative
breast cancer cells [109], which do not express the drug targets of estrogen, progesterone, and human
epithelial growth factor (HER2) receptor. Of all breast cancer patients, 15% have triple-negative breast
cancer [110], which is regarded as very aggressive [111]. The main treatment is surgery, but specific
targets for target-orientated chemotherapeutic agents are missing, and patients suffer from frequent
relapses within the first three years [112]. A more targeted medical treatment would be of great
benefit for these patients. Notably, although (-)-englerin A was selectively cytotoxic to cancer cell
lines, adverse reactions were observed in mice and rats after (-)-englerin A injections [108], which were
mediated by the TRPC4/5 channels [113]. Thus, the therapeutic application of (-)-englerin A might
be limited.
There is evidence that the TRPC5 channel activity increases angiogenesis in cases of breast cancer
by the activation of the transcription factor hypoxia-inducible factor 1 (HIF-1), leading to vascular
endothelial growth factor (VEGF) formation [114], thereby promoting cancer growth. In contrast,
it was reported that the TRPC4 channel activation reduces angiogenesis in cases of renal cell carcinoma
cells by the secretion of the inhibitor of angiogenesis thrombospondin-1 [115]. Moreover, the TRPC4
and TRPC5 channel activation in the endothelial cells increases vasculogenesis [116,117], indicative of
a pro-angiogenetic effect of these channels. Furthermore, the increased expression of TRPC1, TRPC3,
TRPC4, and TRPC6 in ovarian cancer cells increased the migration and proliferation, and therefore
had a tumorigenic effect [118]. Thus, other TRPC channels, like TRPC1, TRPC3, and TRPC6, might
also function as targets for chemotherapeutic agents. However, at present, the majority of publications
point to the TRPC4 and TRPC5 channels as potential new drug targets [119].
The novel role of the NHERF adapter proteins as dynamic regulators of the TRPC4 and TRPC5
channel activity [53,120] might also be important for several other physiological or pathophysiological
processes. Interestingly, the NHERF1 protein/channel interaction is of the utmost importance for the
proper function of CFTR channels. The NHERF1 proteins stabilized and enhanced the membrane
expression of the misfolded CFTR mutant channels [121], which partially restored the channel activity
after the NHERF binding.
The TRPC4 and TRPC5 channels, and the NHERF proteins are co-expressed in various excitable
and non-excitable cells and tissues. Hence, it can be speculated that the inhibitory effect of the
NHERF interaction on the TRPC4/5 channel function may contribute to several physiological
or pathophysiological conditions. For example, in tumor cells, the TRPC4/5 channels and the
NHERF proteins and NHERF mutations account for cancer progression. However, the effect of
the TRPC4/5-NHERF protein complex on tumor growth has largely remained elusive until now.
The NHERF interaction also inhibited the DAG mediated TRPC4/5 channel activation in murine
hippocampal neurons and in proximal tubule cells [53], suggesting a regulatory role. Altogether,
further studies will be needed to show whether the TRPC4/5-NHERF protein complexes have the
potential to serve as novel target structures for therapeutics.
5. Conclusions
The new concept that all TRPC channels are DAG sensitive is not only a new starting point
for deeper insights into the activation mechanism of TRPC channels on a molecular level, but it
might also help to unravel the physiological and pathophysiological roles of these channels, which
have not been fully understood until now. On the molecular level, the conformational changes and
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the kinetics of the conformational changes leading to the TRPC4 and TRPC5 channel activation are
largely elusive, as a structure analysis only revealed the inactive channel states. Moreover, the role
of the NHERF proteins as dynamic regulators of the TRPC4 and TRC5 channel activation sheds
new light on the function of ion channels and adapter proteins in multi-protein complexes. In the
TRPC4/5-NHERF protein complexes, the NHERF proteins suppress the DAG sensitivity. Thus, for
screening purposes, wildtype TRPC5 channels as well as DAG sensitive PKC phosphorylation site
mutant T972A, which cannot interact with NHERF, might be used. Without the inhibitory NHERF
binding, it can be speculated that other hits will be identified. As the expression pattern of NHERF
proteins and TRPC4/5 channels is altered in several cancer cell lines and might be linked to cancer
progression, the TRPC4/5–NHERF channel complexes should also be reconsidered as potential
novel targets for cancer therapeutics. Future studies will have to unravel the physiological and
pathophysiological roles of these channel complexes. However, a thorough analysis of the TRPC
channel functions on a molecular level is of the utmost importance to lay the foundation for a better
understanding of the role of TRPC channels in health and disease.
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